ANNEXON BIOSCIENCES

ANNEXON BIOSCIENCES is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative and autoimmune diseases. ANNEXON BIOSCIENCES' innovative drugs target the loss of neural connections in the brain caused by complement-mediated deficiency, which is associated with Alzheimer's disease and Huntington's disease. The company’s first candidate product, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative diseases. Its second candidate product, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to treat neurodegenerative ophthalmic diseases. ANNEXON BIOSCIENCES is advancing its current programs while evaluating additional orphan drug and large-market indications.